Blood Pressure Treatment Study for Mild High Blood Pressure in Pregnancy
Tests labetalol or nifedipine to lower blood pressure in pregnant people with mild hypertension.
Plain-language title generated from the registry record
Registry title: Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
Key facts
- Where
- Birmingham, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 89 years old?
Source: NCT05989581, who can take part
Where in United States
- UABBirmingham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT05989581
- Record updated
- 11 August 2026
- Original description
The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP<130/80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of <130/80mmHg or usual care to treatment only if BPs ≥140/90mmHg. For this pilot, the investigator will randomize a total of 74 eligible participants, 37 to active treatment to BP<130/80mmHg and 37 to usual care.Read full original descriptionShow less
Treatment of American Heart Association/American College of Cardiology Stage 1 Hypertension in Pregnancy: A Randomized Control Trial
The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP<130/80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of <130/80mmHg or usual care to treatment only if BPs ≥140/90mmHg. For this pilot, the investigator will randomize a total of 74 eligible participants, 37 to active treatment to BP<130/80mmHg and 37 to usual care.
Inclusion: Viable singleton gestation; No fetal anomalies; Blood pressures 130-139/80-89mmHg on two occasions at least 4 hours apart prior to 20 weeks gestation; Planning to deliver at UAB Hospital; No indication for pregnancy termination; Receiving care at the UAB prenatal clinics.
Exclusion: Fetal demise diagnosed prior to enrollment; Known major structural of chromosomal abnormalities prior to enrollment; Known diagnosis of chronic hypertension ( BP ≥ 140/90mmHg) or current antihypertensive medication use; Declines Randomization; Contraindication to first line antihypertensive (Nifedipine/ Labetalol); Comorbidities requiring BP goals < 130/80mmHg.